1. Scrip
  2. >>Business
  3. >>Deals

MEI Gets Another Chance At PI3K Inhibitor With Infinity Merger

 
• By Joseph Haas

Merger plans follow MEI’s recent decision to shelve its own PI3K inhibitor due to class safety concerns. Combined firm will have three clinical oncology candidates, runway into 2025.

M&A
MEI and Infinity announce the latest merger of smaller, clinical-stage biotechs • Source: Shutterstock

Continuing a trend of small companies merging in a tight financial market to increase their runway and R&D shots on goal, MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc. revealed on 23 February that they plan to merge, with a focus on Infinity’s Phase II PI3K inhibitor eganelisib in metastatic head-and-neck cancer as well as two early-stage cancer candidates from MEI.

While both companies are publicly traded, the financing environment is tight across the biopharmaceutical sector, including for clinical-stage companies. (Also see "Finance Watch: Aileron, Talaris, Frequency And The Search For Strategic Alternatives" - Scrip, 21 February, 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

More from Business

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.